News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection
Yakup Ergün/obdh.com.tr
Jan 28, 2025, 17:24

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X about a paper he co-authored with colleagues published in Expert Review of Molecular Diagnostics:

“In the present day, when we have learned that KRAS mutations can be targeted, I was reminded of our research on the selection of backbone chemotherapy.

We had found that irinotecan was superior to oxaliplatin in patients with codon 12 mutations in metastatic KRAS-mutant CRC.”

“KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer”

Authors: Yakup Ergun, Yusuf Acikgoz, Oznur Bal, Gokhan Ucar, Merve Dirikoc, Eda Caliskan Yildirim, Nadiye Akdeniz, Dogan Uncu.

Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection

More posts featuring Yakup Ergün.

cancer CRC Dogan Uncu Eda Caliskan Yildirim Gokhan Ucar KRAS-mutant CRC Merve Dirikoc Nadiye Akdeniz OncoDaily Oncology Oznur Bal Yakup Ergün Yusuf Acikgoz
Special Coverage
Blog
Jan 28, 2025, 17:24
Sohila Karem: Attending the Cairo BGICC has been an incredibly enriching experience
Science
Jan 28, 2025, 17:24
Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Dear FDA, clinical trial diversity is not DEI
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Registration is open for the 22nd Annual PER Winter Lung Cancer Conference
Science
Jan 28, 2025, 17:24
Manel Esteller: Thrilled to introduce our article on mapping the "Hallmarks of Cancer" in human primary tumors
Blog
Jan 28, 2025, 17:23
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Insight
Jan 28, 2025, 17:20
Pashtoon Kasi: Very intriguing to see differences of single agent PD1 vs combination with CTLA4
Blog
Jan 28, 2025, 17:20
Melanoma clinical trial ME17 is officially open for enrollment in Canada - Canadian Cancer Trials Group
Blog
Jan 28, 2025, 17:19
EIOC Journal Club virtual roundtable discussion on the Treatment of Endometrial Cancer
Blog
Jan 28, 2025, 17:18
Pashtoon Kasi: Positive thing to look at ASCO each year is the “incremental” gains in survival
Insight
Jan 28, 2025, 17:18
Sandy Duarte: Rebuilding Your Life Bank - Trusting the Resilience Within
Insight
Jan 28, 2025, 17:17
Kamran Mirza: Honored to be representing the University of Michigan Department of Pathology at the incredible BGICC